Asset
Ziftomenib
Kura Oncology Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06655246 | phase1 | recruiting | 2025-03-27 | 2027-12-01 | Kura Oncology, Inc. | A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) |
| NCT05735184 | phase1 | recruiting | 2023-07-18 | 2030-04-01 | Kura Oncology, Inc. | A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML |
| NCT04067336 | phase1_2 | active_not_recruiting | 2019-09-12 | 2028-10-16 | Kura Oncology, Inc. | First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia |
| NCT06001788 | phase1 | recruiting | 2024-02-22 | 2026-12-01 | Kura Oncology, Inc. | Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia |
| NCT07007312 | phase3 | recruiting | 2025-09-26 | 2031-11-01 | Kura Oncology, Inc. | Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML |
FDA applications (1)
| Application | Type | Applicant |
|---|---|---|
| NDA 220305 | NDA | KURA ONCOLOGY INC |
Marketed products (1)
- KOMZIFTI